CCI okays proposed acquisition of certain stake in Schneider Electric India Pvt Ltd & Schneider Electric JV Holdings 2 Pte. Ltd. (See 'Corp Brief') CCI nod to proposed combination involving Curefit, Cultfit & Fitness First Luxembourg (See 'Corp Brief') SARFAESI - Provident fund dues must be paid out first from auction proceeds of defunct factory, ahead of claims of secured creditor (the bank), with remaining amounts to satisfy other debts: SC (See 'Legal Desk') India Post unveils Kerala's First Gen-Z Post Office Extension Counter at CMS College, Kottayam (See 'Corp Brief') Global Organic Market rises; India strengthens Exports with Revised NPOP (See 'Corp Brief') A&C - Mere use of term 'arbitration' in contractual clause does not by itself establish binding intent to arbitrate unless parties have clearly agreed to resolve their disputes through that process: SC (See 'Legal Desk') MOIL achieves Best-Ever November Production and Sales Performance (See 'Corp Brief') Power Minister commences COD of 250 MW 3rd Unit of Tehri Variable Speed PSP (See 'Corp Brief') Misc - Adequate treatment is available domestically, mere preference for foreign medical facility does not justify permitting accused facing serious economic-offence allegations to leave jurisdiction: HC (See 'Legal Desk') MoS flags Off Tirupati-Sainagar Shirdi Express (See 'Corp Brief') A&C - No party can invoke Section 11 after competent civil court has already rejected Section 8 application by holding that arbitration clause does not constitute arbitration agreement: HC (See 'Legal Desk') FAME outreach, Niveshak Didi scheme promoting safe banking practices: MoS (See 'Corp Brief') Rail Infra proposals Reviewed to Strengthen Integrated Logistics Network (See 'Corp Brief') IBC - Regulation 2B(3) will not justify unilateral forfeiture of entire Earnest Money Deposit, when scheme is rejected on technical grounds: IBBI (See 'Legal Desk') Smart Metering Adoption: 4.76 Crore Smart Meters installed (See 'Corp Brief') UDBHAV 2025: Telangana tops Medal Tally as Tribal Talent shines nationwide (See 'Corp Brief') PMLA - FIRs being fundamental documents based on which entire case was initiated by ED, failure to serve same is fatal omission on part of enforcement directorate: SAFEMA TRIBUNAL (See 'Legal Desk') Australia-India Education and Skills Council meeting to be held in New Delhi (See 'Corp Brief') RM appeals for generous contributions to Armed Forces Flag Day Fund (See 'Corp Brief') The Human Impact of Raipur-Vizag Corridor (See 'Corp Brief') A&C - Court's scope of inquiry u/s 11 is limited to prima facie examination of existence of arbitration agreement while adjudication u/s 8 is to be made for both existence & validity: HC (See 'Legal Desk') HM inaugurates newly-constructed Bio-CNG and Fertilizer Plant by Banas Dairy (See 'Corp Brief') NMDC signs MoU with IIT Kanpur to strengthen Cybersecurity (See 'Corp Brief') Misc - Decision of Lokpal cannot be challenged in judicial review if there is no procedural infirmity or irregularity in manner in which either CVC or Lokpal conducted inquiry: HC (See 'Legal Desk')

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.